Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Long-term health care utilization is greater among patients with COPD who have tested positive for COVID-19 and are unvaccinated.

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the classic male presentation.

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

Patients with COPD and established cardiovascular disease have more MACEs and seek less preventive cardiac care than patients with CVD alone.

Samuel Louie; Amir A Zeki; Michael Schivo; Andrew L Chan; Ken Y Yoneda; Mark Avdalovic; Brian M Morrissey; Timothy E Albertson The Spanish COPD guidelines propose four COPD phenotypes that ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

Rationale Chronic obstructive pulmonary disease (COPD) is the most common indication for domiciliary non-invasive ventilation ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...